Core Insights - Evaxion Biotech A/S has completed dosing for all 16 patients in its phase 2 trial of the personalized cancer vaccine EVX-01, which targets advanced melanoma, and is on track for data readout in the second half of 2025 [1][2] - The trial is designed to evaluate EVX-01 in combination with Merck's KEYTRUDA® (pembrolizumab), with each vaccine tailored to the individual patient's tumor profile [5][7] - Interim data from the trial presented at the ESMO Congress in September 2024 showed a 69% overall response rate, with tumor reduction observed in 15 out of 16 patients, indicating strong potential for EVX-01 as a treatment option [6] Company Overview - Evaxion Biotech A/S is a clinical-stage TechBio company that utilizes its AI-Immunology™ platform to develop personalized vaccines for cancer and other diseases [11] - The company aims to transform patient care by providing innovative and targeted treatment options, with a focus on high unmet medical needs in oncology and infectious diseases [11] Product Details - EVX-01 is a personalized peptide-based cancer vaccine intended for first-line treatment of multiple advanced solid cancers, specifically designed to engage the patient's immune system [4][7] - The vaccine's development leverages AI technology to create tailored therapies based on individual immune characteristics and tumor profiles [4][7]
Evaxion completes dosing in phase 2 trial with personalized cancer vaccine EVX-01